Document:

EX-10.9

 Exhibit 10.9 

GRACE THERAPEUTICS INC. 

AMENDMENT TO CONVERTIBLE NOTE PURCHASE AGREEMENT AND 

AMENDED AND RESTATED CONVERTIBLE PROMISSORY NOTES 

THIS AMENDMENT TO CONVERTIBLE NOTE PURCHASE AGREEMENT AND AMENDED AND RESTATED CONVERTIBLE PROMISSORY NOTES (this
“Amendment”) is made as of [                 , 2020], by and among Grace Therapeutics Inc., a Delaware corporation (the
“Company”), and each of the undersigned purchasers (each a “Purchaser” and together the “Purchasers”). Capitalized terms used but not defined herein shall have the meaning ascribed to such terms in
the Agreement (as defined below). 
 RECITALS 

WHEREAS, pursuant to the convertible note purchase agreement by and between the Company and the Purchasers dated as of
December 1, 2017 (the “Agreement”), the Company issued and sold, and the Purchasers purchased, the convertible promissory notes (the “Original Notes”), due and payable by the Company on December 31, 2018 (the
“Maturity Date”); 
 WHEREAS, on December 17, 2018, the Company and the Purchasers amended, restated, and
replaced the Original Notes in their entirety (the “Amended and Restated Notes”) and extended the Maturity Date to June 30, 2020; 

WHEREAS, pursuant to Section 7(f) of the Agreement and Section 7 of the Amended and Restated Notes, the Agreement
and the Amended and Restated Notes may be amended by the written consent of the Company and the holders of at least sixty six percent (66%) of the then-outstanding principal and interest of the Amended and Restated Notes; and 

WHEREAS, the Company and the undersigned Purchasers who hold all of the presently outstanding principal and interest of the
Amended and Restated Notes desire to amend the Agreement and the Amended and Restated Notes to (1) extend the Maturity Date to September 30, 2021, and (2) permit the Purchasers to convert the Amended and Restated Notes into shares of
the Company’s Equity Securities upon an Exit Transaction (as defined below). 
 NOW, THEREFORE, in consideration of the
premises contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, hereby agree as follows: 

1.    Extension of Maturity Date. The first sentence of Section 1 (Maturity) of the
Amended and Restated Notes is hereby amended in its entirety as follows: 
 Unless converted as provided in Section 2,
this Note will automatically mature and be due and payable on September 30, 2021 (the “Maturity Date”). 

2.    Conversion Upon Exit Transaction. A new Section 2(b) (Conversion Upon Exit
Transaction) shall be added to the Amended and Restated Notes stating exactly as follows: 

2(b)    Conversion Upon Exit Transaction. Prior to the Maturity Date, if the Company proposes to
enter into an agreement pertaining to an Exit Transaction (as defined below) while this Note is outstanding, the Company shall (i) provide the Holder with thirty (30) days’ prior written notice of the closing of such Exit Transaction
(the “Exit Transaction Closing”), and (ii) prior to the Exit Transaction Closing, upon the written 

  
 1 

 
consent of the Holders holding at least sixty six percent (66%) of the then-outstanding principal and interest of the Notes, the entire principal amount of and accrued interest on this Note
shall be converted into shares of the Company’s Equity Securities at a price per share determined based on the lesser of the Company’s valuation (A) of one hundred million dollars ($100,000,000), and (B) obtained by the Company
in connection with the Exit Transaction (the “Exit Transaction Valuation”). In the absence of such written consent of the Holders holding at least sixty six percent (66%) of the then-outstanding principal and interest of the
Notes, prior to the Exit Transaction Closing, the Holder may elect to convert the entire principal amount of and accrued interest on this Note into shares of the Company’s Equity Securities at the Exit Transaction Valuation. The number of
shares of Equity Securities to be issued upon any such conversion pursuant to this Section 2(b) shall be equal to the quotient obtained by dividing the entire principal amount of this Note plus accrued interest by the Exit Transaction Price Per
Share (as defined below), rounded to the nearest whole share. For purposes of this Note, an “Exit Transaction” means (I) a consolidation or merger of the Company with or into any other corporation or other entity or person, or
any other corporate reorganization, other than any such consolidation, merger, or reorganization (y) with an affiliate of the Company, or (z) in which the Equity Securities of the Company immediately prior to such consolidation, merger, or
reorganization continue to represent a majority of the voting power of the surviving entity immediately after such consolidation, merger or reorganization; (II) the transfer of 50% or more of the Equity Securities of the Company, other than in
connection with an equity financing of the Company (for the avoidance of doubt, in which case, Section 2(a), above, may apply); or (III) the sale or transfer of 50% or more of the Company’s assets by value to any non-affiliated
corporation, other entity, or person. “Exit Transaction Price Per Share” means a price per share equal to the quotient of (i) in the case of an Exit Transaction Valuation pursuant to clause (A) above, the Exit Transaction
Valuation divided by the total number of outstanding Equity Securities of the Company immediately prior to the Exit Transaction Closing (giving effect to the exercise or conversion of all securities or rights exercisable for, or convertible into,
Equity Securities of the Company, other than the Notes but including any other convertible promissory notes of the Company), or (ii) in the case of an Exit Transaction Valuation pursuant to clause (B) above, the Exit Transaction Valuation
divided by the total number of outstanding Equity Securities of the Company immediately prior to the Exit Transaction Closing (giving effect to the exercise or conversion of all securities or rights exercisable for, or convertible into, Equity
Securities of the Company, other than the Notes but including any other convertible promissory notes of the Company), multiplied by eighty percent (80%). 

In addition, Section 2(b) of the Amended and Restated Notes (Mechanics and Effect of Conversion) shall be re-titled as Section 2(c)
(Mechanics and Effect of Conversion). 
 3.    Continuance of Agreement and Amended and Restated
Notes. The provisions of the Agreement and the Amended and Restated Notes, as amended hereby, shall remain in full force and effect and unchanged, except as provided herein. If any provision of this Amendment conflicts with the Agreement or
the Amended and Restated Notes, the provisions of this Amendment shall control. This Amendment is binding upon and shall inure to the benefit of the Company and each Purchaser, and their respective successors and permitted assigns. 

4.    Governing Law. This Amendment shall be governed by the internal law of the State of
Delaware. 
 5.    Counterparts. This Amendment may be executed in two or more
counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via electronic mail (including pdf) or other transmission method and any counterpart so
delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. 
 [Remainder of Page
Intentionally Left Blank] 

  
 2 

 IN WITNESS WHEREOF, the parties have executed this Amendment as of
the date first above written. 
  

			
	COMPANY:
	
	 GRACE THERAPEUTICS INC.

		
	 By:
	 	
                  
   

	 Name:

	 Title:

	
	 Address:

	
	PURCHASERS:
	
	 [    ]

		
	 By:
	 	
                  
   

	 Name:

	 Title:

	
	 Address:

  

SIGNATURE PAGE TO AMENDMENT TO CONVERTIBLE
NOTE PURCHASE AGREEMENT 
 AND AMENDED AND
RESTATED CONVERTIBLE PROMISSORY NOTESEX-10.10

 Exhibit 10.10 

GRACE THERAPEUTICS INC. 

AMENDMENT TO CONVERTIBLE NOTE PURCHASE AGREEMENTS 

THIS AMENDMENT TO CONVERTIBLE NOTE PURCHASE AGREEMENTS (this “Amendment”) is made as of
[            , 2018] by and among Grace Therapeutics Inc., a Delaware corporation (the “Company”), and the undersigned Purchasers. Capitalized terms used but not
defined herein shall have the meaning ascribed to such terms in the Original Agreements (as defined below). 
 RECITALS 

WHEREAS, the Company has issued and sold, and the Purchasers purchased, the Notes, convertible into equity securities of the
Company, as a series of convertible promissory notes, issuable pursuant to a series of note purchase agreements on substantially similar terms (collectively, the “Original Agreements”); 

WHEREAS, pursuant to Section 1(b)(iii) of the Original Agreements, the Company intended to sell the Notes within ninety
(90) days of the Initial Closing Date, and, with the Initial Closing Date being June 11, 2018, such 90-day period has concluded; 

WHEREAS, pursuant to Section 7(f) of the Original Agreements, the Original Agreements may be amended by the written
consent of the Company and the holders of at least sixty six percent (66%) of the then-outstanding principal and interest of the Notes; and 

WHEREAS, the Company and the undersigned Purchasers who hold at least sixty six percent (66%) of the presently
outstanding principal and interest of the Notes desire to amend the Original Agreements as set forth herein. 
 NOW,
THEREFORE, in consideration of the premises contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, hereby agree as follows:

 1.    Extension of Final Closing Date. The first sentence of
Section 1(b)(iii) of the Original Agreements is hereby amended in its entirety as follows: 

(iii)    After the Initial Closing, but on or before October 1, 2018, the Company may conduct one or
more additional closings (each, an “Additional Closing”), if any, to be held at such time and place as the Company and the Purchasers participating in each such Additional Closing mutually agree upon, orally or in writing (each, an
“Additional Closing Date”). 
 2.    Continuance of Original Agreements.
The provisions of the Original Agreements, as amended hereby, shall remain in full force and effect and unchanged, except as provided herein. If any provision of this Amendment conflicts with the Original Agreements, the provisions of this Amendment
shall control. This Amendment is binding upon and shall inure to the benefit of the Company and each Purchaser, and their respective successors and permitted assigns. 

3.    Governing Law. This Amendment shall be governed by the internal law of the State of
Delaware. 
 4.    Counterparts. This Amendment may be executed in two or more
counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via electronic mail (including pdf) or other transmission method and any counterpart so
delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. 
 [Remainder of Page
Intentionally Left Blank] 

  
 1 

 IN WITNESS WHEREOF, the parties have executed this Amendment as of
the date first above written. 
  

			
	COMPANY:
	
	 GRACE THERAPEUTICS INC.

		
	 By:
	 	
                  
           

	 Name:

	 Title:

	
	PURCHASERS:
	
	 See attached signature pages.

  

SIGNATURE PAGE TO AMENDMENT TO CONVERTIBLE
NOTE PURCHASE AGREEMENTS

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00330-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00330-of-00352.parquet"}]]